agilon health, inc. 8-K

What Happened agilon health, inc. filed an 8-K (Item 5.07) reporting the results of its annual meeting of stockholders held June 2, 2026 (filed June 3, 2026). Three Class II directors were elected to serve until the 2029 annual meeting: Diana McKenzie, Karen McLoughlin and Ronald Williams. Stockholders also ratified Ernst & Young LLP as the independent registered public accounting firm for fiscal 2026 and approved, on an advisory (non-binding) basis, the company’s executive compensation.

Key Details

• Directors elected (terms to 2029):
  • Diana McKenzie — For: 11,679,958; Against: 177,760; Abstained: 7,034; Broker non-votes: 1,870,677.
  • Karen McLoughlin — For: 9,525,491; Against: 2,332,208; Abstained: 7,053; Broker non-votes: 1,870,677.
  • Ronald Williams — For: 10,837,623; Against: 1,019,347; Abstained: 7,782; Broker non-votes: 1,870,677.
• Auditor ratification (Proposal 2): Ernst & Young LLP ratified — For: 13,712,368; Against: 6,616; Abstained: 16,445.
• Advisory vote on executive compensation (Proposal 3): Approved — For: 11,228,258; Against: 627,870; Abstained: 8,624; Broker non-votes: 1,870,677.

Why It Matters These results show shareholder approval of the company’s nominated board slate, continuity in governance through 2029, and a clean ratification of the independent auditor (Ernst & Young) for 2026—actions that affect oversight and financial reporting. The advisory approval of executive compensation signals shareholder support for pay practices, though it is non-binding and does not change executive contracts. Broker non-votes indicate a material block of shares that were not voted on certain proposals, which can be relevant when assessing the level of active shareholder participation.